Literature DB >> 8095771

Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area.

N M Ampel1, C L Dols, J N Galgiani.   

Abstract

PURPOSE: To determine the incidence of active coccidioidomycosis among subjects infected with the human immunodeficiency virus (HIV) living in an area endemic for coccidioidomycosis and to identify factors associated with the development of active coccidioidomycosis in these patients. PATIENTS AND METHODS: This was a prospective cohort analysis of HIV-infected subjects living in an area endemic for coccidioidomycosis in Arizona. On entry and at approximately 4-month intervals, subjects were interviewed and examined, and had spherulin skin testing and CD4 lymphocyte counts performed along with other tests. During each interval, it was determined whether the subject had developed active coccidioidomycosis according to established criteria.
RESULTS: One hundred seventy subjects entered the study. Median follow-up was 11.3 months (range: 0 to 44 months). Thirteen subjects developed active coccidioidomycosis, with an estimated cumulative incidence of 24.6% by 41 months (95% confidence limits 8.2% and 41.1%). Risk factors associated with the development of active coccidioidomycosis in the cohort were a CD4 lymphocyte count of less than 0.250 x 10(9)/L and a diagnosis of acquired immunodeficiency syndrome. Factors associated with prior coccidioidal infection, including a positive spherulin skin test, length of residence in the endemic area for more than 25 months, and a prior history of coccidioidomycosis, were not associated with the development of active infection.
CONCLUSION: Active coccidioidomycosis among individuals infected with HIV is common in the coccidioidal endemic area. Immunodeficiency appears to be the major risk factor for the development of disease. Evidence of prior coccidioidomycosis, including a positive spherulin skin test, does not appear to predict the development of active infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095771     DOI: 10.1016/0002-9343(93)90054-s

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  40 in total

Review 1.  Female genital coccidioidomycosis (FGC), Addison's disease and sigmoid loop abscess due to Coccidioides immites; case report and review of literature on FGC.

Authors:  A Chowfin; R Tight
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

Review 2.  Measurement of cellular immunity in human coccidioidomycosis.

Authors:  Neil M Ampel
Journal:  Mycopathologia       Date:  2003       Impact factor: 2.574

Review 3.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 4.  Prophylaxis against opportunistic infections in patients infected with the human immunodeficiency virus.

Authors:  L W Cheever; R E Chaisson; J E Gallant
Journal:  West J Med       Date:  1996 Jul-Aug

Review 5.  Coccidioidomycosis: host response and vaccine development.

Authors:  Rebecca A Cox; D Mitchell Magee
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 6.  Endemic mycoses in AIDS: a clinical review.

Authors:  J Wheat
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

Review 7.  Fungal infections: a growing threat.

Authors:  D M Dixon; M M McNeil; M L Cohen; B G Gellin; J R La Montagne
Journal:  Public Health Rep       Date:  1996 May-Jun       Impact factor: 2.792

8.  Disseminated Coccidioidomycosis with Clinically Evident Splenomegaly in an Immunocompetent Host, First Case Reported in the literature.

Authors:  Garrett R Bird; Robert D Libke; John F Billelo; Nancy A Parks; John S Pollard
Journal:  Mcgill J Med       Date:  2009-11-16

Review 9.  Coccidioidomycosis.

Authors:  J N Galgiani
Journal:  West J Med       Date:  1993-08

10.  Antifungals: need to search for a new molecular target.

Authors:  A T Sangamwar; U D Deshpande; S S Pekamwar
Journal:  Indian J Pharm Sci       Date:  2008 Jul-Aug       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.